CO6190537A2 - Vacuna para la enfermedad de lyme canina - Google Patents

Vacuna para la enfermedad de lyme canina

Info

Publication number
CO6190537A2
CO6190537A2 CO09044585A CO09044585A CO6190537A2 CO 6190537 A2 CO6190537 A2 CO 6190537A2 CO 09044585 A CO09044585 A CO 09044585A CO 09044585 A CO09044585 A CO 09044585A CO 6190537 A2 CO6190537 A2 CO 6190537A2
Authority
CO
Colombia
Prior art keywords
vaccine composition
ospc
vaccine
antigen
canine
Prior art date
Application number
CO09044585A
Other languages
English (en)
Inventor
Steven Callister
Rhonda Lafleur
Terri Lee Wasmoen
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of CO6190537A2 publication Critical patent/CO6190537A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1.- Una composición de vacuna la cual comprende una cantidad inmunológicamente efectiva de organismos provenientes de una primera o una única cepa de una genoespecie Borrelia; en donde cuando los organismos de dicha primera o dicha única cepa son cultivados bajo condiciones de crecimiento estándar de la genoespecie Borrelia, son erradicados en presencia de un anticuerpo OspC-específico educido en un animal inyectado con B. burgdorferi ss 50772 (ATCC No. PTA-439). 2.- La vacuna de la reivindicación 1, en donde la cantidad inmunológicamente efectiva de los organismos ha sido inactivada. 3.- La vacuna de la reivindicación 1, en donde dicha primera o dicha única cepa exhibe un antígeno OspC sobre su superficie celular; y en donde los anticuerpos OspC-borreliacídicos son inducidos en un canino en donde dicho canino es inmunizado con dicha composición de vacuna. 4.- La composición de vacuna de la reivindicación 3, en donde una proporción significativa de los anticuerpos OspC-horreliacídicos son específicos para el OspC7. 5.- La composición de vacuna de la reivindicación 3, en donde dicha primera o dicha única cepa es la B. burgdorferi ss 50772 (ATCC No. PTA-439). 6.- La composición de vacuna de la reivindicación 1 que además comprende una cantidad inmunológicamente efectiva de organismos inactivados de una segunda cepa perteneciente de a la genoespecie Borrelia; y en donde dicha segunda cepa exhibe un antígeno OspA, un antígeno OspB, o exhibe tanto un antígeno OspA como un antígeno OspB sobre su superficie celular. 7.- La composición de vacuna de la reivindicación 6, en donde los anticuerpos OspC-borreliacídicos y los anticuerpos OspA-borreliacídicos son inducidos en un canino cuando dicho canino está inmunizado con dicha composición de vacuna.
CO09044585A 2006-11-03 2009-05-04 Vacuna para la enfermedad de lyme canina CO6190537A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86425806P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
CO6190537A2 true CO6190537A2 (es) 2010-08-19

Family

ID=39365056

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09044585A CO6190537A2 (es) 2006-11-03 2009-05-04 Vacuna para la enfermedad de lyme canina

Country Status (17)

Country Link
US (2) US8137678B2 (es)
EP (1) EP2077856B1 (es)
JP (3) JP5177824B2 (es)
KR (1) KR101192127B1 (es)
CN (1) CN101573135B (es)
AU (1) AU2007318026B2 (es)
BR (1) BRPI0719360B1 (es)
CA (1) CA2668405C (es)
CO (1) CO6190537A2 (es)
IL (1) IL198485A0 (es)
MX (1) MX2009004866A (es)
NZ (1) NZ576564A (es)
RU (1) RU2460538C2 (es)
SG (1) SG176451A1 (es)
UA (1) UA99719C2 (es)
WO (1) WO2008057396A2 (es)
ZA (1) ZA200903378B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027504A1 (en) * 1994-04-11 1995-10-19 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
SG176451A1 (en) * 2006-11-03 2011-12-29 Schering Plough Ltd Canine lyme disease vaccine
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
US8313915B2 (en) * 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
US8808705B2 (en) * 2010-10-20 2014-08-19 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
AU2013290596B2 (en) * 2012-07-17 2016-07-21 Boehringer Ingelheim Animal Health USA Inc. Method of providing protective immunity against heterologous Leptospira strains
WO2019110486A1 (en) 2017-12-04 2019-06-13 Intervet International B.V. Canine lyme disease vaccine

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US4002736A (en) 1974-12-16 1977-01-11 Pankratz Duane C Porcine bacterin
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
US4712617A (en) * 1986-10-03 1987-12-15 The Dow Chemical Company Method for controlling the flow of liquids through a subterranean formation
US5246844A (en) 1991-10-22 1993-09-21 Board Of Regents, The University Of Texas System Virulence associated proteins in borrelia burgdorferi (bb)
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US5385826A (en) 1989-04-21 1995-01-31 Gundersen Medical Foundation, Ltd. Diagnostic assay for lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
US5582829A (en) 1990-04-05 1996-12-10 Rx Technologies, Inc. Sonicated borrelia burgdorferi vaccine
SG47447A1 (en) 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ATE196425T1 (de) 1990-07-06 2000-10-15 American Home Prod Impfstoff gegen die lyme-krankheit
US5436000A (en) 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
US6872550B1 (en) 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
EP0877085A1 (en) 1991-08-15 1998-11-11 SMITHKLINE BEECHAM BIOLOGICALS s.a. OspA protein of borrelia burgdorferi subgroups, encoding genes and vaccines
EP0540457A1 (en) 1991-10-22 1993-05-05 Symbicom Ab Improvements in Borrelia burgdorferi diagnosis and prophylaxis
JPH08503194A (ja) 1992-05-26 1996-04-09 スミスクライン・ビーチャム・コーポレイション ライム病の診断および予防に有用な組成物
US6303129B1 (en) 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
US5686078A (en) 1992-09-14 1997-11-11 Connaught Laboratories, Inc. Primary and secondary immunization with different physio-chemical forms of antigen
WO1994006463A1 (en) 1992-09-14 1994-03-31 Pfizer Inc Immortalized cells and uses therefor
WO1994019697A1 (en) 1993-02-26 1994-09-01 Cambridge Biotech Corporation Methods of inducing immunity to lyme disease and a colorimetric assay for borreliacidal activity of antisera
EP0701612B1 (en) * 1993-04-29 1998-01-21 IMMUNO Aktiengesellschaft IMMUNOGENIC FORMULATION OF OspC ANTIGEN VACCINES FOR THE PREVENTION AND TREATMENT OF LYME DISEASE AND RECOMBINANT METHODS FOR THE PREPARATION OF SUCH ANTIGENS
US5656451A (en) 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
WO1995027504A1 (en) * 1994-04-11 1995-10-19 Solvay Animal Health, Inc. Borrelia burgdorferi bacterin
US6150556A (en) 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6861539B1 (en) 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6143788A (en) 1995-03-10 2000-11-07 G.D. Searle & Co. Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
EP1188766A1 (en) 1995-03-10 2002-03-20 G.D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US7339078B2 (en) 1995-03-10 2008-03-04 G.D. Searle Llc Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
WO1997015600A1 (en) 1995-10-26 1997-05-01 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Tick (ixodes scapularis) vector saliva-induced lyme disease spirochete (borrelia burgdorferi) antigens as vaccine candidates
AU1836097A (en) 1996-01-22 1997-08-11 Regents Of The University Of California, The Borrelia burgdorferi outer membrane proteins
US6045804A (en) 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2294701C (en) 1997-06-30 2009-09-08 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
PT1042001E (pt) 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
US20010036658A1 (en) 1997-12-19 2001-11-01 Phillips Steven E. Culture media for growing spirochetes
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
WO2000006745A1 (en) * 1998-07-31 2000-02-10 Gundersen Lutheran Medical Foundation, Inc. Uses of the borreliacidal epitope(s) of borrelia burgdorferi outer surface protein c (ospc) as vaccine
WO2000078345A1 (en) 1999-06-21 2000-12-28 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6517838B1 (en) 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
US20040197339A1 (en) 2003-01-29 2004-10-07 Brown Paul R. Vaccine for Lyme disease
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
GB0315323D0 (en) * 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US20050202046A1 (en) 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7985209B2 (en) 2005-12-15 2011-07-26 Kimberly-Clark Worldwide, Inc. Wound or surgical dressing
US20090324638A1 (en) 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
DE102006045252B4 (de) 2006-09-26 2012-12-27 Euroimmun Medizinische Labordiagnostika Ag Protein-freies Medium für die Kultivierung von Borrelien und dessen Benutzung
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
SG176451A1 (en) * 2006-11-03 2011-12-29 Schering Plough Ltd Canine lyme disease vaccine

Also Published As

Publication number Publication date
CN101573135A (zh) 2009-11-04
JP5177824B2 (ja) 2013-04-10
RU2460538C2 (ru) 2012-09-10
JP2010509217A (ja) 2010-03-25
AU2007318026A1 (en) 2008-05-15
SG176451A1 (en) 2011-12-29
UA99719C2 (ru) 2012-09-25
WO2008057396A3 (en) 2008-10-16
US20080181916A1 (en) 2008-07-31
AU2007318026B2 (en) 2013-04-18
JP2012211205A (ja) 2012-11-01
EP2077856B1 (en) 2015-08-12
KR101192127B1 (ko) 2012-10-17
BRPI0719360A2 (pt) 2014-02-04
CN101573135B (zh) 2013-06-12
WO2008057396A2 (en) 2008-05-15
US8414901B2 (en) 2013-04-09
CA2668405C (en) 2015-05-05
CA2668405A1 (en) 2008-05-15
US20120141530A1 (en) 2012-06-07
ZA200903378B (en) 2010-03-31
EP2077856A2 (en) 2009-07-15
KR20090077018A (ko) 2009-07-13
IL198485A0 (en) 2011-08-01
NZ576564A (en) 2012-03-30
BRPI0719360B1 (pt) 2016-09-06
JP2017019873A (ja) 2017-01-26
JP6073594B2 (ja) 2017-02-01
RU2009120894A (ru) 2010-12-10
MX2009004866A (es) 2009-05-19
US8137678B2 (en) 2012-03-20
WO2008057396A8 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
CO6190537A2 (es) Vacuna para la enfermedad de lyme canina
Földvári et al. Dermacentor reticulatus: a vector on the rise
Angel et al. Distribution and seasonality of vertically transmitted dengue viruses in Aedes mosquitoes in arid and semi-arid areas of Rajasthan, India
Rollend et al. Transovarial transmission of Borrelia spirochetes by Ixodes scapularis: a summary of the literature and recent observations
Desvars et al. Similarities in Leptospira serogroup and species distribution in animals and humans in the Indian ocean island of Mayotte
AR055708A1 (es) Composicion de acaros, uso de la misma, metodo para criar un acaro predatorio phytoseiid, sistema de crianza para criar dicho acaro predatorio phytoseiid y metodos para el control biologico de pestes en un cultivo
RU2020119271A (ru) Вакцина для защиты от streptococcus suis
AR085633A1 (es) Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos
Bockenstedt et al. What ticks do under your skin: two-photon intravital imaging of Ixodes scapularis feeding in the presence of the lyme disease spirochete
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
GT200300180A (es) Vacunas para enfermedades reproductoras del ganado
MX2008013619A (es) Aumento del titulo para vacunacion en animales.
CO6251273A2 (es) Composiciones para vacuna en emulsion que comprenden antigeno y un adyuvante en la fase acuosa y su metodo de elaboracion
Butler et al. Borrelia burgdorferi infections with special reference to horses. A review
Robinson et al. BCG vaccination against tuberculosis in European badgers (Meles meles): a review
AR039429A1 (es) Metodo para aumentar la eliminacion especifica mediada por la respuesta inmune endogena de la poblacion de celulas patogenicas en un animal huesped inmunizado previamente, composicion y combinacion que comprenden un auxiliar th1 y un conjugado hapten-portador de utilidad en el mismo.
Leschnik et al. Species, developmental stage and infection with microbial pathogens of engorged ticks removed from dogs and questing ticks
Scott et al. Lyme disease bacterium, Borrelia burgdorferi sensu lato, detected in multiple tick species at Kenora, Ontario, Canada
Sood et al. The emergence and epidemiology of Lyme Borreliosis in Europe and North America
AR071104A1 (es) Metodo para determinar una proteina de haemophilus parasuis que comprende un determinante antigenico de reaccion cruzada
Thomas et al. The importance of Rickettsiales infections
Gabriel et al. Ecology of Anaplasma phagocytophilum infection in gray foxes (Urocyon cinereoargenteus) in northwestern California
Burr et al. Current perspectives on canine leptospirosis
Adetunji et al. Seroprevalence of Borrelia burgdorferi antibodies in white-tailed deer from Texas
Kean et al. Lyme disease: aetiopathogenesis, factors for disease development and control

Legal Events

Date Code Title Description
FC Application refused